Alkermes plc $ALKS Stake Lessened by Vanguard Group Inc.

Vanguard Group Inc. trimmed its stake in shares of Alkermes plc (NASDAQ:ALKS) by 1.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 18,179,511 shares of the company’s stock after selling 323,563 shares during the quarter. Vanguard Group Inc. owned approximately 11.01% of Alkermes worth $545,385,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the stock. Tidal Investments LLC grew its stake in Alkermes by 1.1% in the second quarter. Tidal Investments LLC now owns 35,130 shares of the company’s stock worth $1,005,000 after purchasing an additional 395 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its position in shares of Alkermes by 1.5% in the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 33,120 shares of the company’s stock worth $948,000 after acquiring an additional 502 shares in the last quarter. Amalgamated Bank increased its holdings in shares of Alkermes by 1.1% in the 2nd quarter. Amalgamated Bank now owns 46,848 shares of the company’s stock valued at $1,340,000 after acquiring an additional 528 shares during the last quarter. Envestnet Asset Management Inc. lifted its stake in Alkermes by 1.3% during the second quarter. Envestnet Asset Management Inc. now owns 43,658 shares of the company’s stock worth $1,249,000 after purchasing an additional 551 shares during the last quarter. Finally, Arizona State Retirement System boosted its holdings in Alkermes by 1.4% in the third quarter. Arizona State Retirement System now owns 46,340 shares of the company’s stock worth $1,390,000 after purchasing an additional 639 shares during the period. Institutional investors and hedge funds own 95.21% of the company’s stock.

Insider Transactions at Alkermes

In related news, EVP Craig C. Hopkinson sold 9,000 shares of the stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $33.93, for a total transaction of $305,370.00. Following the completion of the sale, the executive vice president directly owned 57,740 shares of the company’s stock, valued at $1,959,118.20. This represents a 13.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Shane Cooke sold 61,200 shares of Alkermes stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $34.57, for a total transaction of $2,115,684.00. Following the completion of the transaction, the director owned 103,744 shares in the company, valued at approximately $3,586,430.08. This trade represents a 37.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 148,148 shares of company stock valued at $5,028,378 over the last three months. 4.40% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

ALKS has been the topic of a number of recent research reports. Weiss Ratings restated a “hold (c+)” rating on shares of Alkermes in a research report on Monday, December 29th. Wall Street Zen lowered Alkermes from a “strong-buy” rating to a “buy” rating in a report on Sunday, November 9th. Wolfe Research started coverage on Alkermes in a research report on Monday. They set an “outperform” rating and a $45.00 price target on the stock. Jefferies Financial Group set a $56.00 target price on Alkermes and gave the stock a “buy” rating in a research report on Tuesday, October 28th. Finally, Zacks Research lowered shares of Alkermes from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 19th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $44.00.

Alkermes Trading Up 3.7%

ALKS stock opened at $33.39 on Wednesday. The firm’s 50-day moving average is $31.38 and its two-hundred day moving average is $30.17. The company has a market capitalization of $5.51 billion, a price-to-earnings ratio of 16.53 and a beta of 0.49. Alkermes plc has a 52 week low of $25.17 and a 52 week high of $36.32.

Alkermes (NASDAQ:ALKS) last announced its earnings results on Wednesday, February 25th. The company reported $0.29 EPS for the quarter, missing the consensus estimate of $0.43 by ($0.14). Alkermes had a return on equity of 21.81% and a net margin of 22.27%.The firm had revenue of $384.55 million for the quarter, compared to the consensus estimate of $380.44 million. On average, equities research analysts predict that Alkermes plc will post 1.31 earnings per share for the current year.

Key Stories Impacting Alkermes

Here are the key news stories impacting Alkermes this week:

• Positive Sentiment: Wolfe Research initiated coverage with an “outperform” rating, giving the stock fresh buy-side attention that can support upward momentum. Wolfe Research initiation
• Positive Sentiment: Revenue slightly exceeded expectations: $384.6M vs. consensus $380.4M, and the company reported healthy profitability (net margin ~22.3%, ROE ~21.8%), which supports valuation metrics. Q4 press release
• Neutral Sentiment: Management provided financial expectations for 2026 and hosted an earnings webcast; guidance details (and how conservative/aggressive they are) will be closely watched in the call. Earnings release and guidance
• Neutral Sentiment: CEO succession announced: long-time CEO Richard Pops will retire July 31, 2026; COO Blair Jackson will become CEO Aug. 1 and join the board, with Pops remaining chairman — an orderly transition but one investors will monitor for strategic continuity. CEO succession plan
• Neutral Sentiment: Alkermes highlighted recent corporate events including the close of the Avadel acquisition and upcoming investor presentations (TD Cowen conference) — these can influence sentiment as more detail on integration and synergies emerges. Avadel acquisition context Conference presentation
• Negative Sentiment: Earnings per share missed consensus materially: $0.29 vs. $0.43 expected (a $0.14 shortfall), a key driver of near-term downside risk until management addresses drivers of the miss. Q4 press release

Alkermes Profile

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.